What should a patient tell the anesthesia team before surgery or sedation while using Wegovy?

Inform your anesthesia team that you use Wegovy and the date of your last dose, as it can increase aspiration risk by delaying stomach emptying.

Why Anesthesia Teams Must Know About Wegovy Use

Wegovy (semaglutide) belongs to a class of medications called GLP-1 receptor agonists. A primary way these drugs work is by slowing down gastric emptying, which means food and liquid stay in your stomach for a longer period. This helps with satiety and weight loss but poses a specific risk during anesthesia.

When a patient is under general anesthesia or deep sedation, the body's protective airway reflexes, such as coughing and swallowing, are suppressed. This makes the airway vulnerable.

Pulmonary aspiration occurs when stomach contents enter the lungs. Because of the stomach's high acidity, this can cause serious complications, including chemical pneumonitis (inflammation), infection, pneumonia, and acute respiratory distress syndrome (ARDS).

If your stomach is not empty due to Wegovy's effect on digestion, you are at a significantly higher risk for aspiration during a procedure. Anesthesiologists rely on pre-operative fasting to ensure the stomach is empty, but GLP-1 medications can make this standard fasting period insufficient.

What Specific Information to Provide

Clearly state the name of the medication you are taking: "Wegovy" or "semaglutide." Do not just say you are on a "weight loss shot," as this is too vague for a clinical risk assessment. If you are on another GLP-1 like Ozempic, Rybelsus, Mounjaro, or Zepbound, you must disclose that as well.

Provide the exact date and, if possible, the time of your last injection. This is the most critical piece of information for the anesthesia team. It helps them determine the potential for residual drug effects on your gastric motility.

Inform them of your current dose (e.g., 1.7 mg, 2.4 mg) and the frequency of your injections (weekly for Wegovy). Also mention if you have recently started the medication or increased your dose, as side effects like nausea can be more pronounced.

Be sure to report any gastrointestinal symptoms you may be experiencing, such as nausea, vomiting, abdominal bloating, or feelings of fullness. The presence of these symptoms can indicate more significant gastric slowing and a higher risk.

ASA Guidelines for GLP-1 Agonists and Surgery

The American Society of Anesthesiologists (ASA) has issued specific guidance on managing patients on GLP-1 agonists before surgery to enhance safety. These recommendations help standardize care and reduce the risk of aspiration.

For patients on a weekly GLP-1 injection like Wegovy, the ASA suggests considering holding the medication for one week before the elective procedure or surgery. This provides time for the drug's effect on gastric emptying to diminish.

The decision to hold a medication should always be made in consultation with the prescribing physician, considering the risks and benefits for the patient's underlying condition (e.g., diabetes management). Never stop your medication without medical guidance.

If the medication was not held for the recommended period, or if the patient has significant GI symptoms, the anesthesia team may need to take additional precautions. This could involve treating the patient as if they have a "full stomach," potentially altering the anesthesia plan or even postponing the procedure if it is not an emergency.

Potential Consequences if This Is Overlooked

The most severe consequence is pulmonary aspiration, which can lead to life-threatening lung injury and prolonged hospital stays. This is the primary safety concern that all pre-operative protocols are designed to prevent.

For your own safety, your surgery may be cancelled or postponed on the day of the procedure if the anesthesia team determines the aspiration risk is too high. While frustrating, this decision is made to protect you from harm.

In some cases, the anesthesiologist may perform a point-of-care gastric ultrasound. This non-invasive test uses an ultrasound probe on the abdomen to visualize the stomach and assess whether it contains significant amounts of solid or liquid material.

Ultimately, the anesthesia professional will conduct a thorough risk assessment based on the information you provide, the type of surgery, and the type of anesthesia required. Open and honest communication is the best tool to ensure a safe outcome. GOAL.MD's physician-supervised programs emphasize patient education on these important safety topics, which you can learn more about on our site.

Bottom Line

You must tell your surgeon and your anesthesia team that you are taking Wegovy (semaglutide) as early as possible before any planned surgery or procedure requiring sedation.

Be prepared to share the specific name of the drug, your dose, and the date of your last injection. This information is critical for the anesthesia team to make an informed safety plan for your care.

Follow the pre-operative instructions from your medical team precisely. This may include pausing your Wegovy injection for a week before your procedure, but do not make any changes to your medication schedule without consulting your physician.

This article is for informational purposes only and does not constitute medical advice. Always consult with your healthcare provider for any questions about your medications and upcoming procedures.

Generated from GOAL.MD's physician-reviewed source library. This page has not received its own physician review. Physician-supervised telehealth. More at goal.md/answers.